Home » Pipeline
Pipeline
August 12, 2019
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Precigen, Inc. | PRGN-3005 UltraCAR-T | advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer | Phase 1 trial initiated |
| Soricimed Biopharma, Inc. | SOR-C13 | late stage pancreatic cancer | Phase 1b trial initiated enrolling 36 subjects with advanced solid tumor cancers at The University of Texas MD Anderson Cancer Center (MDACC) |
| 89Bio Ltd. | BIO89-100 | nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD) and high risk of NASH | Phase 1b/2a trial initiated enrolling 83 subjects |
| Provention Bio, Inc. | PRV-3279 | lupus | Phase 1b/2a trial initiated enrolling 16 healthy volunteers |
| Eureka Therapeutics, Inc. | ET140202 ARTEMIS T-Cell therapy | advanced hepatocellular carcinoma (HCC) liver cancer | Phase 1/2 trial initiated enrolling subjects with metastatic or locally advanced, inoperable liver cancer and have progressed or have not been able to tolerate at least one line of treatment at City of Hope in Duarte, CA |
| RegeneRx Biopharmaceuticals, Inc. | RGN-137 | epidermolysis bullosa (EB) | Phase 2 trial initiated |
| POXEL SA | PXL770 | NASH | Phase 2a trial initiated enrolling 100 subjects with nonalcoholic fatty liver disease (NAFLD) who likely have NASH at sites in the U.S. |
| Altavant Sciences | rodatristat ethyl | pulmonary arterial hypertension (PAH) | Phase 2a trial initiated enrolling 36 subjects |
| Astellas Pharma, Inc. | fezolinetant | moderate-to-severe vasomotor symptoms (VMS) | Phase 3 trial initiated enrolling 450 subjects at 20 sites in the U.S., Canada and Europe |
| Apyx Medical Corporation | next-generation J-Plasma Precise Handpiece | open and laparoscopic surgical procedures | 510(k) clearance granted by the FDA |
| Alnylam Pharmaceuticals, Inc. | givosiran | acute hepatic porphyria (AHP) | Priority Review granted by the FDA |
| Provention Bio, Inc. | teplizumab (PRV-031) | prevention or delay of clinical type 1 diabetes (T1D) in at-risk individuals | Breakthrough Therapy designation granted by the FDA |
| Inotrem S.A. | nangibotide (LR12) | septic shock | IND approval granted by the FDA |
| Daiichi Sankyo | Turalio (pexidartinib) capsules | subjects with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery | Approval granted by the FDA |
| Bracco Diagnostics, Inc. | VARIBAR THIN LIQUID (barium sulfate) for oral suspension | dysphagia | Approval granted by the FDA |
